Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.

Tierens A, Bjørklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, Forestier E, Hasle H, Jahnukainen K, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L, Abrahamsson J.

Br J Haematol. 2016 Aug;174(4):600-9. doi: 10.1111/bjh.14093. Epub 2016 Apr 13.

PMID:
27072379
2.

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K.

Blood Cancer J. 2014 Oct 10;4:e250. doi: 10.1038/bcj.2014.69.

3.

Bacterial infection (BI)-INDEX: an improved and simplified rapid flow cytometric bacterial infection marker.

Nuutila J, Jalava-Karvinen P, Hohenthal U, Kotilainen P, Pelliniemi TT, Nikoskelainen J, Lilius EM.

Diagn Microbiol Infect Dis. 2014 Feb;78(2):116-26. doi: 10.1016/j.diagmicrobio.2013.10.016. Epub 2013 Oct 31.

PMID:
24315569
4.

Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.

Nuutila J, Jalava-Karvinen P, Hohenthal U, Kotilainen P, Pelliniemi TT, Nikoskelainen J, Lilius EM.

Hum Immunol. 2013 May;74(5):522-30. doi: 10.1016/j.humimm.2013.01.011. Epub 2013 Jan 29.

PMID:
23376460
5.

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.

Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K.

Br J Haematol. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. No abstract available.

PMID:
23206270
6.

A rapid flow cytometric method for distinguishing between febrile bacterial and viral infections.

Nuutila J, Jalava-Karvinen P, Hohenthal U, Kotilainen P, Pelliniemi TT, Nikoskelainen J, Lilius EM.

J Microbiol Methods. 2013 Jan;92(1):64-72. doi: 10.1016/j.mimet.2012.11.005. Epub 2012 Nov 12.

PMID:
23154042
7.

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.

Putkonen M, Kairisto V, Juvonen V, Pelliniemi TT, Rauhala A, Itälä-Remes M, Remes K.

Eur J Haematol. 2010 Nov;85(5):416-23. doi: 10.1111/j.1600-0609.2010.01510.x.

PMID:
20722702
8.

Prognostic evaluation of COX-2 expression in renal cell carcinoma.

Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen SO, Salminen EK.

Anticancer Res. 2010 Jul;30(7):3023-30.

PMID:
20683050
9.

ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status.

Hämäläinen M, Juvonen V, Häikiö S, Lakkala T, Johansson J, Pelliniemi TT, Salmi TT, Remes K, Kairisto V.

Eur J Haematol. 2010 Oct;85(4):361-2. doi: 10.1111/j.1600-0609.2010.01483.x. Epub 2010 Jul 13. No abstract available.

PMID:
20546020
10.

Evaluation of the effects of different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia.

Paananen P, Arola MO, Pelliniemi TT, Salmi TT, Lähteenmäki PM.

J Pediatr Hematol Oncol. 2009 Oct;31(10):745-9. doi: 10.1097/MPH.0b013e3181b794d0.

PMID:
19734805
11.

Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.

Korja M, Jokilammi A, Salmi TT, Kalimo H, Pelliniemi TT, Isola J, Rantala I, Haapasalo H, Finne J.

BMC Cancer. 2009 Feb 17;9:57. doi: 10.1186/1471-2407-9-57.

12.

Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.

Putkonen M, Rauhala A, Pelliniemi TT, Remes K.

Ann Hematol. 2009 Jul;88(7):673-80. doi: 10.1007/s00277-008-0675-5. Epub 2009 Jan 13.

PMID:
19139894
13.

Severe congenital neutropenia and pegfilgrastim.

Lähteenmäki PM, Jahnukainen K, Pelliniemi TT, Kainulainen L, Salmi TT.

Eur J Haematol. 2009 Jan;82(1):75-6. doi: 10.1111/j.1600-0609.2008.01145.x. Epub 2008 Sep 4. No abstract available.

PMID:
18774955
14.

Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.

Itälä M, Huhtinen AR, Juvonen V, Kairisto V, Pelliniemi TT, Penttilä TL, Rauhala A, Tienhaara A, Remes K.

Eur J Haematol. 2008 Aug;81(2):100-6. doi: 10.1111/j.1600-0609.2008.01082.x. Epub 2008 Apr 10.

PMID:
18410542
15.

Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.

Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Aurén J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT.

Eur J Haematol. 2008 Mar;80(3):201-7. Epub 2007 Dec 10.

PMID:
18081724
16.
17.

Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.

Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi TT, Remes K, Ruutu T, Savolainen ER, Siitonen T, Silvennoinen R, Volin L, Elonen E; Finnish Leukaemia Group.

Eur J Haematol. 2007 Jun;78(6):477-86. Epub 2007 Mar 28.

PMID:
17391337
18.

Renal impairment compromises the use of total homocysteine and methylmalonic acid but not total vitamin B12 and holotranscobalamin in screening for vitamin B12 deficiency in the aged.

Loikas S, Koskinen P, Irjala K, Löppönen M, Isoaho R, Kivelä SL, Pelliniemi TT.

Clin Chem Lab Med. 2007;45(2):197-201.

PMID:
17311508
19.

Vitamin B12 deficiency in the aged: a population-based study.

Loikas S, Koskinen P, Irjala K, Löppönen M, Isoaho R, Kivelä SL, Pelliniemi TT.

Age Ageing. 2007 Mar;36(2):177-83. Epub 2006 Dec 21.

PMID:
17189285
20.

The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma.

Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S, Salminen E.

Anticancer Res. 2006 Sep-Oct;26(5B):3825-33.

21.

Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients.

Putkonen M, Rauhala A, Itälä M, Kauppila M, Pelliniemi TT, Remes K.

Haematologica. 2005 Apr;90(4):562-3.

22.

No bias between the first and the new version of radioimmunoassay for serum holo-transcobalamin by Axis-Shield.

Loikas S, Pelliniemi TT, Koskinen P.

Clin Chem Lab Med. 2004 May;42(5):569-70. No abstract available.

PMID:
15202798
23.

Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial.

Koskela K, Pelliniemi TT, Pulkki K, Remes K.

Leuk Lymphoma. 2004 Apr;45(4):749-54.

PMID:
15160951
24.

[A young women with hypochromic microcytotic anemia unresponsive to iron therapy].

Järveläinen H, Juvonen V, Pelliniemi TT.

Duodecim. 2004;120(1):80-3. Finnish. No abstract available.

PMID:
14976812
25.

Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle.

Ruutu T, Koivunen E, Nousiainen T, Pelliniemi TT, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, Remes K, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E; Finnish Leukaemia Group.

Eur J Haematol. 2004 Jan;72(1):38-44.

PMID:
14962261
26.

Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.

Björkstrand B, Rasmussen T, Remes K, Gruber A, Pelliniemi TT, Johnsen HE.

Eur J Haematol. 2003 Jun;70(6):379-83.

PMID:
12756020
27.

Autologous blood cell transplantation in multiple myeloma: impact of CD34+ cell selection with long follow-up.

Remes K, Itälä M, Kauppila M, Pelliniemi TT, Rajamäki A.

J Hematother Stem Cell Res. 2003 Feb;12(1):63-70.

PMID:
12662437
28.

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.

Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamäki E, Remes K.

Bone Marrow Transplant. 2003 Mar;31(5):347-51.

PMID:
12634725
29.

RIA for serum holo-transcobalamin: method evaluation in the clinical laboratory and reference interval.

Loikas S, Löppönen M, Suominen P, Møller J, Irjala K, Isoaho R, Kivelä SL, Koskinen P, Pelliniemi TT.

Clin Chem. 2003 Mar;49(3):455-62.

30.

Autocrine production and synergistic growth-promoting activity of interleukin-6 and oncostatin M in a new human myeloma cell line TU-1.

Koskela K, Pelliniemi TT, Pelliniemi LJ, Remes K, Södeström KO, Punnonen K, Kumar R, Ollikainen H, Pulkki K.

Acta Haematol. 2002;107(1):23-8.

PMID:
11818668
31.

Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.

Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H, Salminen E.

Cancer. 2001 Aug 15;92(4):761-7.

PMID:
11550145
32.

[Peripheral blood smear preparation].

Pelliniemi TT.

Duodecim. 1998;114(12):1177-84. Review. Finnish. No abstract available.

PMID:
11524763
33.

Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis.

Koskela K, Pelliniemi TT, Rajamäki A, Pulkki K, Remes K.

Eur J Haematol. 2000 Jul;65(1):52-6.

PMID:
10914939
34.

Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections.

Itälä M, Pelliniemi TT, Remes K, Vanhatalo S, Vainio O.

Leuk Lymphoma. 1998 Dec;32(1-2):165-74.

PMID:
10037012
35.

Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.

Elonen E, Almqvist A, Hänninen A, Jansson SE, Järventie G, Koistinen P, Koivunen E, Lahtinen R, Lehtinen M, Nousiainen T, Pelliniemi TT, Rajamäki A, Remes K, Timonen T, Vilpo J, Volin L, Ruutu T.

Leukemia. 1998 Jul;12(7):1041-8.

36.

Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.

Koskela K, Pelliniemi TT, Lakkala T, Remes K.

Bone Marrow Transplant. 1998 Feb;21(3):305-7.

37.

p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.

Ollikainen H, Syrjänen S, Koskela K, Pelliniemi TT, Pulkki K.

Scand J Clin Lab Invest. 1997 Jul;57(4):281-9.

PMID:
9249875
38.

High-dose chemotherapy with autologous stem cell support for the treatment of advanced ovarian cancer--initial experience in Uppsala and Turku.

Grenman S, Tholander B, Remes K, Kauppila M, Rajamäki A, Pelliniemi TT, Rantanen V, Salmi T, Carlsson K, Hóglund M, Oberg G, Simonson B, Salmi T.

Acta Obstet Gynecol Scand. 1997 Apr;76(4):363-8. Review.

PMID:
9174433
39.

Autologous blood cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield.

Itälä M, Pelliniemi TT, Rajamäki A, Remes K.

Bone Marrow Transplant. 1997 Apr;19(7):647-51.

40.

Type I diabetic pregnancy and subclinical human papillomavirus infection.

Hietanen S, Ekblad U, Pelliniemi TT, Syrjänen K, Helenius H, Syrjänen S.

Clin Infect Dis. 1997 Feb;24(2):153-6.

PMID:
9114140
41.

Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

Ruutu T, Hänninen A, Järventie G, Koistinen P, Koivunen E, Kätkä K, Nousiainen T, Oksanen K, Pelliniemi TT, Remes K, Timonen T, Volin L, Elonen E.

Leuk Res. 1997 Feb;21(2):133-8.

PMID:
9112430
42.

Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery.

Remes K, Matinlauri I, Grenman S, Itälä M, Kauppila M, Pelliniemi TT, Salminen E, Vanharanta R, Rajamäki A.

J Hematother. 1997 Feb;6(1):13-9.

PMID:
9112214
43.

[From bone marrow transplantation to blood stem cell transplantation. Experiences from the first 100 autologous stem cell transplantation in Turku].

Remes K, Rajamäki A, Grenman S, Itälä M, Kauppila M, Nikoskelainen J, Pelliniemi TT, Ristamäki R, Salmi TT, Salmi T, Salminen E, Vanharanta R, Toivanen A.

Duodecim. 1997;113(3):219-28. Finnish. No abstract available.

PMID:
11370030
44.

Serum oncostatin M in multiple myeloma: association with prognostic factors.

Koskela K, Pelliniemi TT, Remes K, Rajamäki A, Pulkki K.

Br J Haematol. 1997 Jan;96(1):158-60.

PMID:
9012701
45.

Febrile infection changes the expression of IgG Fc receptors and complement receptors in human neutrophils in vivo.

Leino L, Sorvajärvi K, Katajisto J, Laine M, Lilius EM, Pelliniemi TT, Rajamäki A, Silvoniemi P, Nikoskelainen J.

Clin Exp Immunol. 1997 Jan;107(1):37-43.

46.
47.

Effects of alpha-interferon on serum beta-2-microglobulin.

Remes K, Tienhaara A, Pelliniemi TT.

Leuk Lymphoma. 1996 Apr;21(3-4):233-8. Review.

PMID:
8726404
48.

Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.

Pulkki K, Pelliniemi TT, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R.

Br J Haematol. 1996 Feb;92(2):370-4.

PMID:
8603002
49.

[Interleukin-6 reflects the disease severity and prognosis of myeloma].

Pelliniemi TT, Pulkki K.

Duodecim. 1996;112(7):563-5. Finnish. No abstract available.

PMID:
10592621
50.

IL-6-receptor-mediated growth inhibition by all-trans retinoic acid but not by interferon-alpha in human myeloma cells.

Pulkki K, Neva M, Koskela K, Ollikainen H, Remes K, Pelliniemi TT.

Ann N Y Acad Sci. 1995 Jul 21;762:457-8. No abstract available.

PMID:
7668556

Supplemental Content

Loading ...
Support Center